Compare III & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | VYGR |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | 1500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.7M | 203.6M |
| IPO Year | 2006 | 2015 |
| Metric | III | VYGR |
|---|---|---|
| Price | $4.13 | $3.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.50 | ★ $16.50 |
| AVG Volume (30 Days) | 195.4K | ★ 748.0K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | ★ 216.67 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $192,745,000.00 | $10,135,000.00 |
| Revenue This Year | $3.85 | $34.04 |
| Revenue Next Year | $4.34 | $7.92 |
| P/E Ratio | $80.30 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $3.74 | $2.88 |
| 52 Week High | $6.45 | $5.55 |
| Indicator | III | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 34.98 |
| Support Level | $3.88 | $2.96 |
| Resistance Level | $4.33 | $4.33 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 81.72 | 5.19 |
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.